NATCOPHARM price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- NATCOPHARM
- MB Code
- MBEQU51
- ISIN
- INE987B01026
- BSE code
- 524816
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 739.1 Cr
- Net profit
- 233.3 Cr
- EPS
- 14.96
- YoY revenue
- -39.47%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for NATCOPHARM
Natco Pharma shares fell up to 14.85% on May 29 after Q4 FY26 profit dropped 34% year-on-year to Rs 269 crore and revenue fell to Rs 816.…
Natco Pharma's Q4FY26 net profit fell 34% to ₹269 crore as revenue dropped 39.5% and EBITDA 77%; margins shrank sharply, and the stock sa…
Natco Pharma shares fell 12% after Q4 net profit dropped 34% to Rs 268 crore, while revenue from operations fell 39.5% to Rs 739 crore fr…
Natco Pharma fell 14% after Q4FY26 results showed net profit and revenue dropping more than 39% year on year, disappointing investors.
Dividend of ₹1.50 per share
Ex-date corporate action
Feb 16 2026: Natco Pharma jumped 11.24% after CDSCO approved generic Semaglutide injection; company plans India launch in March 2026. Q3 …
EPS 8.46 vs est. 1.22
Beat estimates by 591.18%
Natco Pharma has received USFDA approval for its generic cancer drug Erdafitinib, a competitor to Janssen's Balversa, with expected US sa…
Price returns
Historical performance
Technicals
Indicator consensus